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The F4/80 antigen, encoded by the Adgre1 locus, has been widely-used as a
monocyte-macrophage marker in mice, but its value as a macrophage marker in other
species is unclear, and has even been questioned. ADGRE1 is a seven transmembrane
G protein-coupled receptor with an extracellular domain containing repeated Epidermal
Growth Factor (EGF)-like calcium binding domains. Using a new monoclonal antibody,
we demonstrated that ADGRE1 is a myeloid differentiation marker in pigs, absent
from progenitors in bone marrow, highly-expressed in mature granulocytes, monocytes,
and tissue macrophages and induced by macrophage colony-stimulating factor (CSF1)
treatment in vivo. Based upon these observations, we utilized RNA-Seq to assess
the expression of ADGRE1 mRNA in bone marrow or monocyte-derived macrophages
(MDM) and alveolar macrophages from 8 mammalian species including pig, human,
rat, sheep, goat, cow, water buffalo, and horse. ADGRE1 mRNA was expressed by
macrophages in each species, with inter-species variation both in expression level and
response to lipopolysaccharide (LPS) stimulation. Analysis of the RNA-Seq data also
revealed additional exons in several species compared to current Ensembl annotations.
The ruminant species and horses appear to encode a complete duplication of the 7
EGF-like domains. In every species, Sashimi plots revealed evidence of exon skipping
of the EGF-like domains, which are highly-variable between species and polymorphic in
humans. Consistent with these expression patterns, key elements of the promoter and
a putative enhancer are also conserved across all species. The rapid evolution of this
molecule and related ADGRE family members suggests immune selection and a role in
pathogen recognition.
Keywords: macrophage, monocyte, bone marrow, F4/80, porcine, ADGRE1/EMR1, adhesion G protein-coupled
receptor E1
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INTRODUCTION
The F4/80 antigen, first identified by Austyn and Gordon (1),
was rapidly adopted as a marker for cells of the mononuclear
phagocyte lineage in mice (2). F4/80 expression varies amongst
mouse mononuclear populations, being very low or absent from
osteoclasts, macrophages of T cell areas and marginal zone, lung
alveolar macrophages, and the majority of classical dendritic cells
[reviewed in (3)]. High expression of F4/80 has been proposed
as a marker for populations of mouse tissue macrophages that
derive from embryonic progenitors and renew independently of
blood monocytes (4). The isolation of F4/80 cDNA (5) revealed
that it encodes a large extracellular domain containing multiple
Epidermal Growth Factor (EGF)-like calcium-binding domains,
linked to a seven-transmembrane domain characteristic of G
protein coupled receptors. The mouse gene encoding the F4/80
antigen was given the name Emr1 (EGF module-containing
mucin-like receptor) based upon homology to a previously-
identified human cDNA (6). Subsequent studies identified related
receptors (EMR2, EMR3, EMR4, CD97) collectively called EGF-
TM7 proteins (5). These receptors are a subfamily of adhesion
G protein coupled receptors (ADGRE) (7) and Emr1 has been
renamed Adgre1. Despite the high level of expression and lineage
restriction in mouse mononuclear phagocytes, the knockout of
Adgre1 in themouse germ line produced few phenotypic impacts,
apart from apparent dysregulation of autoimmune responses and
generation of regulatory T cells (8). One possible explanation for
the lack of phenotype in mutant mice is the existence of a closely-
related gene, Adgre4 (EMR4), which is also expressed in mouse
monocyte-macrophage lineage cells (9, 10). Adgre1mRNA is also
highly-expressed by rat macrophages (11, 12).
Rodent macrophages differ significantly from humans in
both constitutive and inducible gene expression profiles (13–
15). In humans, ADGRE1 has been proposed as an eosinophil-
specific marker. Monoclonal antibodies produced against the
human protein bound specifically to eosinophils, and ADGRE1
mRNA was apparently enriched in these cells compared to
mononuclear phagocytes (16, 17). F4/80 antibody also binds
to mouse eosinophils (18, 19). Adgre1 mRNA in mice is also
expressed by neutrophils, although the protein is not present
on the cell surface (20). The apparent lack of ADGRE1 in
human monocyte-macrophages is not likely to be compensated
by ADGRE4 which was annotated as a pseudogene, due to a
one base deletion which alters the reading frame before the
transmembrane domains. The ADGRE4 transcript, if expressed,
could potentially encode a secreted extracellular domain, with
the open reading frame encoding the seven-transmembrane
domain retained intact and containing a start codon, and so is
potentially translated separately (21). However, by contrast to
rodents, the human genome contains two additional members
of the EGF-TM7 family, ADGRE2 and ADGRE3, which are both
highly-expressed in myeloid cells (22). The receptors encoded
Abbreviations: ADGRE1, Adhesion G protein coupled receptor E1; BMDM, bone
marrow-derived macrophages; CSF1, colony-stimulating factor 1; EGF, epidermal
growth factor; HI-FCS, heat inactivated fetal calf serum; MDM, monocyte-derived
macrophages; PBS-T, PBS containing 0.05% Tween-20.
by these genes might fulfill functions mediated by ADGRE1 in
rodents.
We have previously characterized peripheral bloodmonocytes
and macrophages in the domestic pig and shown that pigs
resemble humans in their patterns of constitutive and inducible
gene expression (23–25). Pigs are increasingly recognized as a
superior predictive model for the innate immune system and
the pathology of human disease (26). We showed previously that
ADGRE1 mRNA is highly-expressed in several macrophage-rich
pig tissues, and strongly-induced in the liver, associated with
macrophage infiltration, following treatment with macrophage
colony-stimulating factor (CSF1) (27). CSF1 treatment of mice
was shown to increase the level of F4/80 on individual
macrophages (28) and Adgre1 mRNA was also strongly-induced
in the liver of rats treated with CSF1 (12). Here we describe
the production and characterization of an anti-pig ADGRE1
monoclonal antibody. The antibody binds strongly to monocytes
and granulocytes in bone marrow and blood, and to tissue
macrophages.
Our laboratory has also generated RNA-Seq expression
profiles of CSF1-stimulated macrophages from rats and from
multiple large animal species, including pig, sheep, goat, cow,
water buffalo, and horse (29, 30). There are numerous human
macrophage RNA-Seq datasets available in the public domain.
Based upon the macrophage-enriched expression in the pig, we
(re)examined the expression and complex alternative splicing of
ADGRE1 in each of these species. We conclude that ADGRE1 is
highly-expressed and regulated in macrophages in large animals,
but that both the protein-coding sequence and the transcriptional
regulation is divergent amongst species. We discuss the rapid
evolution of these genes in mammals and speculate on their
possible function.
MATERIALS AND METHODS
Ethics Statement
Approval for this research was obtained fromThe Roslin Institute
and University of Edinburgh Protocols and Ethics Committees.
All experiments were carried out under the authority of a
UK Home Office Project Licence under the regulations of the
Animals (Scientific Procedures) Act 1986.
Primary Cell Isolation and Culture
Isolation of primary pig bone marrow, peripheral blood
mononuclear cells (PBMCs) and alveolar macrophages was
carried out as described previously (24, 25) and all cells
were cultured in full RPMI-1640 medium containing 10%
HI-FCS (Sigma), 1mM Glutamax, 100 U/ml penicillin and
100µg/ml streptomycin (Invitrogen). Primary pig bone marrow
cell cultures were supplemented with 104 Units/ml rh-CSF1
to produce bone marrow-derived macrophages (BMDM) as
described elsewhere (24).
In-vivo Treatment With pCSF1-Fc
Recombinant Protein
Large white pigs were treated with pCSF1-Fc recombinant
protein as previously described (27). In summary 8.5 week old
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animals were injected subcutaneously on three consecutive days
with pCSF1-Fc (0.75 mg/kg; n = 6) or PBS control (n = 5).
Blood was taken and all animals weighed 4 days prior to the first
injections. Animals were euthanized by captive bolt following
sedation with ketamine and azaperone, following which cells of
interest were isolated and frozen for future analysis. Cells from a
subset of these animals were utilized herein.
Construction of Sus scrofa ADGRE1
Chimeric Expression Vector
The full-length cDNA sequence of Sus scrofa ADGRE1
(Ensembl S. scrofa 10.2) was amplified using the primers
fwd 5′-GGTCCTCACTCAATCTGCAAG-3′ and rev 5′-
GGAACAGCATTTTGGAAAGC-3′, then cloned into
pGEM R©-T Easy vector (Promega). The cDNA encoding
the four N-terminal extracellular EGF-like domains (1,082 bp)
was extracted from the pGEM R©-T Easy vector by PCR then
cloned in frame into the EcoRI-EcoRV site of the pFUSE–hIgG1-
Fc2 vector (InvivoGen) and sequenced by Edinburgh Genomics.
We note that subsequent to our study, there are now sequences
for pig ADGRE1 (GACC01000182.1/JAA53625.1) and ADGRE4
(GACC01000180.1/JAA53627.1) mRNA and proteins in the TSA
archives.
Recombinant Protein Production
HEK293T cells grown in DMEM media supplemented with
10% Ig-depleted HI-FCS (Sigma), 1mM Glutamax, 100
U/ml penicillin and 100µg/ml streptomycin (Invitrogen)
were transiently transfected with pADGRE1-pFUSE-hIgG1-
Fc2 DNA at a ratio of 1:1 with Lipofectamine 2000 (Life
Technologies) following manufacturer’s instructions. Four days
post-transfection, the supernatant was harvested, centrifuged
to remove debris and filter sterilized. Soluble protein was then
purified using a HiTrap Protein G column (GE Healthcare) and
desalted using Slide-A-LyzerTM G2 Dialysis Cassettes 1–3mL
10K MWCO (Life Technologies). The recombinant protein
was used as an immunogen for monoclonal antibody (mAb)
production.
Monoclonal Antibody Production
BALB/c mice were purchased from Charles River Laboratories
(UK). Hybridoma production was performed as previously
described (31). In brief, three BALB/c femalemice received a total
of three subcutaneous immunisations with 50 µg of pADGRE1-
hIgG1-Fc2 recombinant protein and TiterMax Gold adjuvant
(Sigma) at least 14 days apart. Immune response was determined
by screening sera collected from all mice prior to immunization
and after the second and subsequent injections by indirect ELISA.
A final intraperitoneal immunization of 50 µg protein in PBS
without adjuvant was given and 4 days later splenocytes were
harvested.
Splenocytes were fused with Sp2/0-Ag14 mouse myeloma
cells (32) at a ratio of 5:1 using polyethylene glycol 1500
(Sigma), following standard procedures. Following fusion, fused
hybridoma cells were grown in RPMI-1640 media supplemented
with 10% IgG-depleted HI-FCS, 1mM Glutamax, HAT Media
Supplement Hybri-MaxTM (Sigma), Hybridoma Fusion and
Cloning Supplement (HFCS, Roche), recombinant mouse IL-
6 (Sigma), 100 U/ml penicillin, and 100µg/ml streptomycin.
After seven to 10 days cells were switched to RPMI-1640
containing 10% IgG-depleted HI-FCS, 1 mM/l Glutamax, HT
Media Supplement Hybri-Max, mouse IL-(6.25 ng/µl)6, 100
U/ml penicillin and 100µg/ml streptomycin. An indirect ELISA
was performed to identify hybridomas producing antibodies
against porcine ADGRE1. Positive wells were expanded and
subcloned to single cell colonies by limiting dilution. Supernatant
was collected and purified by Protein G HiTrap column, with
desalting carried out using Slide-A-LyzerTM G2 Dialysis Cassettes
1–3mL 10K MWCO.
The mAbs were isotyped using IsoStrip Mouse Monoclonal
Antibody Isotyping Kit (Roche) according to manufacturer’s
instructions.
Detection of Pig ADGRE1 Protein by
Indirect ELISA
Indirect ELISA was performed as previously described (33). In
brief, microplates were coated with 50 µg of 1µg/ml pADGRE1-
pFUSE-hIgG1 or Human IgG1-Fc recombinant protein (R&D
Systems) diluted in coating buffer and incubated at 4◦C
overnight. The following day plates were blocked in PBS, 1%
BSA, 1% horse serum for 1 h, followed by three washes with PBS-
0.05% Tween20. Fifty microliters of pre- or post-immune serum
diluted 1:200 in PBS, neat supernatant from hybridoma cloning
plates or 1µg/ml purified mAb in PBS was added to individual
wells and incubated for 1 h at room temperature. Following a
further three washes in PBS-0.05% Tween20 50 µl of horse anti-
mouse IgG-HRP (Cell Signaling) diluted 1:5,000 in PBS was
added and incubated for 1 h at room temperature. After three
further washes peroxidase activity was visualized using TMB
Substrate (BD Biosciences). The reaction was stopped with 2N
hydrochloric acid. A Multiskan Ascent spectrophotometer was
used to read absorbance at 450 nm.
Flow Cytometry
One million cells per sample were first blocked using PBS, 2%
normal horse serum for 15min on ice, then incubated with
either neat supernatant for initial screening or a 1:100 dilution
of Alexa-Fluor-647 conjugated purified mAb for 30min on ice.
Conjugation was performed using a commercially available kit
(Molecular Probes) according to manufacturer’s instructions.
Signal was detected on unconjugated supernatant by incubation
with anti-mouse IgG-allophycocyanin (1:400; BioLegend) for
30min on ice. Following 3 washes in PBS, cells were re-suspended
in 0.1% Sytox Blue (Invitrogen) in PBS for analysis using a
Fortessa LSR flow cytometer (BD Biosciences). Double staining
included mouse anti-pig CD14-FITC (1:50; BioRad), mouse
anti-pig CD16-PE (1:200, BioRad), mouse anti-pig CD163-
PE (1:100, BioRad) and mouse anti-pig SIRP-alpha-PE (1:400,
Southern Biotech). Relevant isotype controls were included in all
experiments. Data collection was performed using Diva software
(BD Biosciences) and analysis using FlowJo v10 software. Welch’s
t-tests were performed on data and results are presented as
treatment group means ± SE. All statistical analyses were
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performed using GraphPad Prism 6.0 (GraphPad Software). A p
< 0.05 was considered statistically significant.
Immunohistochemistry for ADGRE1 and
CD163
Tissues were placed in phosphate buffered saline solution pH7
and mounted in OCT. Frozen sections (10µm) were cut and
mounted on Superfrost slides, then dried for 24 h at 4◦C
prior to use. The slides were fixed for 10min in ice cold
methanol then washed 2 × 5min in PBS. To block endogenous
peroxidase activity the slides were incubated in 0.3% hydrogen
peroxide (H2O2) in PBS then washed 2 × 5min in PBS.
The slides were incubated for 1 h in a humidified chamber
at room temperature in Tris-buffered saline with 20% normal
goat serum and 5% BSA, then washed 2 × 5min in PBS.
Immunostaining was performed using primary mAbs against
mouse anti-pig ADGRE1 (ROS-4E12-3E6, 2.4 ng/µL) andmouse
anti-human CD163 (2 ng/µL, BioRad); control slides had no
primary antibody added. Slides were incubated overnight at
4◦C then washed 2 × 5min in PBS. The primary antibodies
were detected using anti-mouse IgG polymer (Vector MP-
7402) incubated at room temperature for 1 h then washed 2 ×
5min in PBS. The signal was detected using DAB peroxidase
substrate (Vector Laboratories SK-4100) then washed 2 × 5min
in water. Sections were counterstained with haematoxylin and
eosin using a Leica Autostainer XL. Slides were then mounted,
and microscopic analysis performed using the NanoZoomer-XR
(Hamamatsu).
Sources of RNA-Seq Data
RNA-Seq data was previously generated by our lab for BMDM,
or monocyte-derived macrophages (MDM) of rat, cattle, water
buffalo, sheep, goat, pig and horse. All RNA-Seq libraries
were paired-end, the read length for rat was 90 bp, for goat
was 75 bp and for the remainder of the species was 124–
126 bp. RNA-Seq data was also available for a subset of
these species (sheep, water buffalo and goat) from alveolar
macrophages. The sheep data was published as part of a
comprehensive transcriptional atlas (34). A subset of data
from the remaining species was previously analyzed in a
comparative study of the regulation of genes involved in arginine
metabolism and nitric oxide production (35), which generated
gene-level expression estimates, as transcripts per million
(TPM), using Kallisto v0.43.0 (36). The primary RNA-Seq
data is available in the European Nucleotide Archive (ENA)
using NCBI BioProject IDs PRJEB21180 (water buffalo),
PRJEB19199 (sheep), PRJEB22535 (cattle, unpublished),
PRJEB23119 (pig), PRJEB24920 (horse), PRJEB22553 (rat,
unpublished), and PRJEB23196 (goat). Human alveolar
macrophage, microglia, non-classical monocyte, and classical
monocyte datasets were obtained from, respectively, Pinilla-
Vera et al. (37); 10 RNA-Seq libraries within NCBI BioProject
PRJNA428090, representing 6 untreated and 4 LPS-treated
samples), Galatro et al. (38); 39 RNA-Seq libraries within
NCBI BioProject PRJNA387182), Williams et al. (39); 17
RNA-Seq libraries within NCBI BioProject PRJNA339968), and
Mirsafian et al. (40); 1 RNA-Seq library within NCBI BioProject
PRJNA264020).
RESULTS
Production and Characterization of a
Monoclonal Antibody Against Pig ADGRE1
Bone marrow-derived macrophages and alveolar macrophages
from the pig were previously profiled as part of a transcriptional
atlas project (41). However, at the time of development of
the microarray platform used, the ADGRE1 locus was not
annotated. The predicted pig cDNA was truncated at the 5′ end
and missed the start codon. The longest ADGRE1 cDNA for
the pig currently in Ensembl (version 91) predicts a protein
of 939 amino acids with an extracellular domain containing
7 EGF-like calcium-binding domains, as in the mouse. The
predicted amino acid sequence is only around 60% identical
to mouse and almost all the variation resides in these EGF-
like domains. The longest human cDNA in Ensembl encodes
6 EGF-like domains. Cross-species alignment of mouse and
pig cDNA with the human genome reveals that there is an
additional candidate exon encoding a seventh EGF-like domain
in the human genome (not shown). We have confirmed the
expression of this exon in human macrophage RNA-Seq data
as discussed below. Including this exon, the longest human
ADGRE1 protein is predicted to be 940 amino acids. A recent
study (42) utilized RNA-Seq from pig alveolar macrophages to
improve the annotation of genes within the pig immunome.
Within that project, the alveolar macrophage data were used to
assemble two alternative pig ADGRE1 cDNAs. As part of the
ongoing annotation of the pig genome, we have produced RNA-
Seq data from pig BMDM grown in CSF1 and stimulated with
LPS (29).
Based upon the gene expression data, and emerging evidence
that pigs provide a useful model for the study of human
macrophage biology (26), we decided to make an antibody
against the pig protein, with the expectation that it could (a)
enable studies of ADGRE1 function in a relevant model, (b)
confirm the expression of the ADGRE1 protein in macrophages,
and (c) potentially cross-react with human ADGRE1. Previous
antibodies against human ADGRE1 were produced in hamsters,
against a cell-expressed ADGRE1-CD97 fusion protein (16) and
in mice, against a full length ADGRE1 extracellular domain-
Fc fusion protein (17). As an immunogen, we constructed
cDNA, expressed and purified a pig ADGRE1-Fc fusion
protein, immunized mice, and screened hybridomas for specific
binding to the fusion protein, but not to the human IgG
recombinant tag. From amongst 29 primary hybridomas, eight
were cloned, and each produced clones that bound specifically
to the immunogen. One mAb, ROS-4E12-3E6, was selected
for further detailed characterization. The remaining hybridoma
supernatants were screened for cross-reactivity against human
and cattle blood monocytes and sheep alveolar macrophages,
but none were cross-reactive to any other species. This is
likely a reflection of the extensive sequence divergence between
the species.
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Expression of ADGRE1 by Pig Leukocytes
We first examined surface expression of ADGRE1 in PBMC.
Figure 1A shows that mAb ROS-4E12-3E6 bound to monocytes,
identified in this case by their size and granularity profile. In
PBMCs, ADGRE1 was highly-expressed on the entire CD14++
monocyte population (Figure 1B). By contrast to humans, where
the gene is duplicated, CD16 is not regulated in monocyte
subsets in pigs and is uniformly high on the CD14++ population
(23). Accordingly, ADGRE1 was uniform on all CD16++ cells
(Figure 1C). The ADGRE1-negative, CD16lo cells are most
likely natural killer cells. The haptoglobin receptor, CD163,
provides a marker for monocyte differentiation in pigs that
varies inversely with CD14, with CD163hi cells resembling
intermediate monocytes in humans (23). Here, ADGRE1
expression did not vary with the level of expression of CD163
(Figure 1D).
The differentiation of the non-classical monocyte subset in
other species depends upon CSF1 (43) and in mice, F4/80 is also
induced further in tissue macrophages following CSF1 treatment
(28). We previously developed a porcine CSF1-Fc fusion protein,
with an enhanced greater circulating half-life (44). Injection of
this protein into mice (44) or pigs (27) led to a substantial
increase in blood monocyte and tissue macrophage numbers.
Analysis of a subset of samples stored from the previous pig study
confirmed that CSF1-Fc treatment significantly increased the
percentage of ADGRE1+/CD14+ blood monocytes (Figure 1E),
as well as the proportion of ADGRE1+/CD16++ (Figure 1F) and
ADGRE1+/CD163++ monocytes (Figure 1G) within the PBMC
fraction, when compared to cells from control animals. This
result is consistent with the monocytosis described previously
and supports the use of ADGRE1 as a pig monocyte marker.
The median level of surface ADGRE1 was also increased on
the monocytes from CSF1-Fc treated pigs (Figure 1H). In
mice, the F4/80 antigen is expressed at very low levels on
isolated alveolar macrophages (45). By contrast, and consistent
with gene expression profiles reported by Dawson et al. (42),
the level of cell surface ADGRE1 was uniformly exceptionally
high on pig alveolar macrophages (Figure 1I). The identity of
these cells as alveolar macrophages was confirmed by the co-
expression of high levels of SIRP-alpha (CD172a), which is
highly-expressed by monocytes and macrophages in the pig
(23).
These initial observations indicated that ADGRE1 is highly-
expressed on the surface of monocytes and macrophages in
pigs, but with a distinct pattern compared to rodents. We
next considered whether ADGRE1 was widely distributed
amongst myeloid cell lineages, and whether it might provide a
useful differentiation marker. Figure 2A shows that ADGRE1
was detected on presumptive granulocytes in bone marrow
(SSChi). In the bone marrow mononuclear cell fraction, a
minor population of larger cells was ADGRE1hi, presumably
the resident bone marrow macrophages, whereas expression
was low and variable on small mononuclear cells. Figure 2D
shows the fluorescence histogram, indicating relative uniformity
of expression of ADGRE1 amongst the positive cells in
unstimulated bone marrow. When bone marrow cells were
cultivated in rhCSF1, the ADGRE1+/SSChi granulocyte
population largely disappeared within 3 days (Figure 2B),
consistent with the short half-life of granulocytes in culture.
At the same time, there was an evident expansion of an
SSClo, presumptive macrophage population, that had higher
levels of ADGRE1 (Figure 2E). After 7 days in rhCSF1
the population of bone marrow cells, largely comprised of
adherent macrophages as previously described (24), was entirely
SSClo and ADGRE1+ (Figure 2C). At this time, the level of
expression of ADGRE1 on individual cells was heterogeneous
(Figure 2F).
To confirm the expression of ADGRE1 on resident tissue
macrophages, we stained sections of liver and lung. Compared
to the negative control (Figure 3A) and CD163 positive
control (Figure 3B) sections there was abundant expression
of ADGRE1 on lung macrophages (Figure 3C), including
stellate interstitial macrophages and more rounded, presumptive
alveolar macrophages. ADGRE1 mRNA was previously detected
in expression profiles of whole pig liver and was massively
induced by CSF1-Fc treatment (27). Compared to negative
(Figure 3D) and CD163 (Figure 3E) positive sections, high
levels of expression of ADGRE1 was also detected on stellate
Kupffer cells in pig liver (Figure 3F), showing the same portal-
centrilobular gradient observed in mouse liver (46).
The Regulated Expression of ADGRE1
mRNA in Human Macrophages
Two previous reports used RT-PCR to determine the expression
of ADGRE1 in human myeloid cell populations, and concluded
that the mRNA was highly-expressed in eosinophils, and
low or undetectable in other leukocyte populations (16,
17). This conclusion was at odds with the detection of
the mRNA in mononuclear cells in the original cloning of
human EMR1 cDNA (6). Given the expression of ADGRE1
in the pig, we concluded that either pigs are fundamentally
different from humans, or the previous studies of ADGRE1
expression in humans were incorrect. To address these
two possibilities, we examined a range of data available
in the public domain. An expression atlas of human cell
populations generated based upon public domain microarray
data indicates that ADGRE1 mRNA is expressed at similar
levels in neutrophils, monocytes, and alveolar macrophages
[(47); see data on www.biogps.org). The FANTOM5 consortium
used cap-analysis of gene expression (CAGE, genome-scale 5′
end tag sequencing) to analyze monocyte subsets, monocyte-
derived macrophages, activated monocytes and macrophages,
and many other myeloid populations (48, 49). The data can
be visualized on the ZENBU viewer (http://fantom.gsc.riken.
jp/zenbu/). This confirms ADGRE1 is expressed in human
eosinophils, but the level of expression was no higher than
in CD16++ monocytes. Transcription of ADGRE1 in all the
human myeloid lineages appears to be a differentiation marker,
as expected, since mRNA was not detected in CD34+ stem cells
or committed myeloid progenitors. Data from Maiga et al. (50)
also indicate the high expression of ADGRE1 in monocytes and
relative absence from progenitors. The FANTOM5 data also
reveal that ADGRE1 was repressed in MDM grown in CSF1,
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FIGURE 1 | The expression of ADGRE1 on blood leukocytes in the pig. Flow cytometry was carried out on pig PBMCs (A–H) and alveolar macrophages (I).
Representative flow cytometry images are illustrated (n = 3) for live cells (identified by exclusion using Sytox blue). Where shown, quadrant gates were set using
isotype matched control antibody staining. Peripheral blood mononuclear cells were examined for expression of ADGRE1 using monoclonal antibody ROS-4E12-3E6
(A) and positive cells (red) were identified. Multiple color flow cytometry was used to determine the co-expression of ADGRE1 with CD14 (B), CD16 (C), and CD163
(D) on PBMCs. Expression of ADGRE1 with CD14 (E), CD16 (F), and CD163 (G) was also determined in PBMC from pigs treated in-vivo with pCSF1-Fc treatment.
The mean percentage ADGRE1 positive cells ± SE is shown comparing control pigs (B–D) with pCSF1-Fc treated pigs (E–G). *P < 0.05 by Welch’s t-test; n = 3 pigs
per treatment. Note that these samples are a subset of a larger cohort from our previous study (27) in which CSF1-Fc was shown to increase the blood monocyte
count (P < 0.0001). (H) Histogram of ADGRE1 median fluorescence intensity in PBMC from pCSF1-Fc treated pigs (red), control animals (black), and isotype controls
(blue and green for control and treated respectively); n = 3. Expression of ADGRE1 was measured on CD172a+ macrophages from bronchoalveolar lavage (I); n = 3.
relative to the higher level of expression in blood monocytes but
was strongly induced in MDM relatively late in the time course
by LPS. Indeed, the highest expression of ADGRE1 detected in
the FANTOM5 dataset was observed in LPS-stimulated cells (30).
Comparative analysis ofmonocytes,MDMand isolatedmicroglia
(38) by RNA-Seq confirmed both monocyte expression and
relative down-modulation in MDM. The increased expression
of ADGRE1 mRNA in CD16++ human monocytes detected
by CAGE is confirmed in three published microarray datasets
(51, 52). A furthermarker, SLAN, dissects the CD16++monocyte
subpopulation still further, withADGRE1mRNA further elevated
in the SLAN-positive population (53). ADGRE1 mRNA was
very highly expressed in human alveolar macrophages (54,
55) and isolated placental macrophages (56) enriched in the
macrophage fraction isolated from human adipose tissue (57)
and was readily detected in RNA-Seq data derived from human
peritoneal macrophages (58). Taken together, all the evidence
indicates that ADGRE1 is robustly expressed in the human
macrophage lineage and is not eosinophil-restricted. In humans,
the related gene ADGRE4 is located immediately adjacent to
the ADGRE1 locus. In mice, this gene, also known as FIRE
(9, 10), is located around 1.5mb downstream of ADGRE1 on
chromosome 17. Human ADGRE4 is annotated as a pseudogene,
based upon the analysis of a cDNA that contains a 1 bp
deletion relative to the ADGRE4 gene in other primates, which
shifts the reading frame before the transmembrane domain
(21, 59). The FANTOM5 data places the transcription start
site (TSS) around 7 kb upstream of the published cDNA. Since
ADGRE4 mRNA in other species (mouse, rat, dog, and pig)
is around 50-100 bp longer at the 5′ end than human, and
since there is one fewer annotated exon compared to mouse,
it seems likely that there is an alternative 5′ non-coding exon.
ADGRE4 CAGE tags were even more enriched than ADGRE1
in CD16++ monocytes, compared to CD14++ monocytes. In
common with many other monocyte differentiation markers,
the CD14+/CD16+ intermediate monocytes expressed ADGRE4
at intermediate levels (49). Hence, ADGRE4 is a novel marker
for “non-classical” monocytes in humans. The human genome
contains two other genes, ADGRE2 and ADGRE3, related to
ADGRE1 and ADGRE4 and located in the same region of
chromosome 19. Consistent with previous reports (60, 61) in
the FANTOM5 data, ADGRE2 shows a very similar pattern of
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FIGURE 2 | The expression of ADGRE1 in bone marrow progenitors and response to CSF1. Flow cytometry was performed on pig bone marrow cells. Representative
flow cytometry images are illustrated (n = 3) for live cells (identified by exclusion using Sytox blue). Bone marrow cells were examined for expression of ADGRE1 using
monoclonal antibody ROS-4E12-3E6 (red) and the identity of the ADGRE1 positive cells inferred based on size (FSC) and granularity (SSC). ADGRE1 positive cells are
shown in red (A). Bone marrow cells were cultivated in rhCSF1 for 3 days (B) or 7 days (C) and expression of ADGRE1 measured by flow cytometry. The median
expression of ADGRE1 was also measured at days 0, 3, and 7 (D–F, respectively). Isotype control staining is shown (black line).
FIGURE 3 | Immunohistochemical localisation of ADGRE1 in pig tissues. Immunohistochemical staining was carried out on frozen pig liver (A–C) and lung (D–F)
tissue. Representative images are shown (n = 3). Tissues were incubated without primary antibody (negative control A,D), antibody recognizing CD163 (positive
control B,E) and monoclonal antibody ROS-4E12-3E6 recognizing ADGRE1 (C,F). Scale bar =100µm.
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regulation in human monocytes and MDM to ADGRE1, whereas
ADGRE3 is more highly-expressed and restricted to granulocytes,
neutrophils and eosinophils.
ADGRE1, ADGRE2, ADGRE3, and ADGRE4
Expression in Macrophages of Other
Species
As part of the generation of transcriptional atlases for several
mammalian species, and a comparative analysis of macrophage-
expressed genes (29) we have produced deep RNA-Seq data for
rat, sheep, goat, cattle, water buffalo, pig, and horse macrophages
produced by the cultivation of bone marrow cells in CSF1 using
methods originally developed for the pig (24). We utilized these
data to assess the expression of ADGRE1 and ADGRE4 and the
response to LPS, in each of these species. Table S1 summarizes
the expression of ADGRE1 and the related ADGRE4 mRNA
in BMDM, and the response to LPS, for each of the species
examined, including human data from published RNA-Seq
profiles. Where available, additional data is shown for isolated
alveolar macrophages and for monocyte-derived macrophages.
Several findings emerge from these data. Firstly, the highest level
of ADGRE1 mRNA expression detected was in rat BMDM, but
ADGRE1 was robustly expressed in macrophages in all of the
species. Secondly, the level and pattern of expressionwas variable,
even between ruminant species. For example, ADGRE1 was
highly-expressed in BMDM from sheep, 10-fold lower in cattle
and water buffalo (but LPS-inducible as in human macrophages)
and very low in goat. Where we have data available ADGRE1 was
highly expressed in alveolar macrophages in every large animal
species. Of the species examined, only the pig had high expression
of ADGRE4 in BMDM. Like the mouse, the rat has only three
members of the ADGRE family, Adgre1, Adgre4, and Adgre5 (62)
and Adgre1 mRNA was very highly-expressed in rat BMDM.
However, by contrast to mouse, Adgre4 was barely-detectable in
these cells.
ADGRE2 and ADGRE3 are not well annotated in livestock
species, and clear orthology relationships are unclear. For
example, in Ensembl build 11.1, there are now 4 ADGRE2-
like (ENSSSCG00000036342,ENSSSCG00000021675,ENSSSC
G00000013788,ENSSSCG00000013785) and 2 ADGRE3-like
(ENSSSCG00000013787, ENSSSCG00000026402) genes. In
Ensembl, at this time ADGRE2- and ADGRE3-like genes are
annotated as many-to-many orthologs with the other livestock
species. We have included expression estimates for these
transcripts in pig macrophages in Table S1. Only the two
ADGRE3-like genes have significant expressions, and then
10-fold lower than ADGRE1 or ADGRE4.
Evidence of Species-Specific Exon
Skipping in ADGRE1
The EGF-like calcium binding domains of ADGRE1 are encoded
by single exons and can potentially be alternatively spliced.
McKnight and Gordon (63) described 5 isoforms of mouse, and
4 isoforms of human ADGRE1, in which variable numbers of
EGF-like domains are expressed, from none to 7 in mouse, and
1 to 6 in human. These authors did not report the expression of
the seventh EGF-like domain in humans. With the deep RNA-
Seq data available for multiple species we examined the extent
of alternative splicing in each species by aggregating available
macrophage datasets, as shown in Sashimi plots in Figures 4A,B.
These data indicate that the pig and human genomes, like the
rat, encode a maximum of 7 EGF-like transmembrane domains.
The accurate mapping of the RNA-Seq outputs to exons, and
especially analysis of splice junctions, is complicated by the
presence of an internal duplication in each of these species.
The longest predicted cDNA for any species in Ensembl is
for sheep, but the RNA-Seq data indicates the existence of
a previously unannotated exon (Figure 4B). Even with the
mapping limitations imposed by the repeated structure of the
gene, the Sashimi plots indicate that in each species, every
exon encoding an EGF-like domain can probably be bypassed
by an exon skipping event. Accordingly, the potential number
of isoforms may be large, although limitations of the datasets,
including varying read lengths, mean that additional testing is
required to increase statistical confidence in this hypothesis. The
level of heterogeneity suggested is, however, supported by the
broad band detected on the northern blot analysis of mouse
macrophages when mouse Adgre1 cDNA was originally cloned,
with the apparent size ranging over at least 1 kb (5).
Analysis of the Promoter and Enhancer of
Adgre1
A number of alternative isoforms originally described for human
and mouse ADGRE1 appear to encode N-terminally truncated
proteins (63). However, a single major TSS region for ADGRE1
is indicated from the FANTOM5 CAGE data from mouse and
human macrophages, and we have confirmed the TSS region
in CAGE data generated from pig BMDM (64) and from water
buffalo (LL, RY, DAH, unpublished observations). Based upon
the conserved expression in macrophages, we anticipated that
regulatory elements would also be conserved. Accordingly, we
extracted genomic sequences from Ensembl to compare the
predicted transcription start sites and promoters for all of the
species examined. The promoter in all species is TATA-less, and
purine-rich, conforming to the pattern seen in many myeloid
promoters in which the macrophage-specific transcription factor
PU.1 is a key determinant of transcription initiation (65). The
precise start site is conserved between the three species for which
we have CAGE data (DAH, unpublished observations). Based
upon these data, we can align the promoter sequences of mouse,
rat, human, horse, pig, cattle, goat, sheep, and water buffalo
as shown in Figure 5A. The promoter contains a perfectly-
conserved binding site for C/EBP transcription factors, and for
the Maf and MafB transcription factors which have both been
shown, through the use of knockout mutations, to control F4/80
(Adgre1) expression in mice (66, 67). Analysis of the mouse
Adgre1 promoter revealed the presence of at least 9 purine-rich
motifs containing the consensus GGAA core binding sites for
PU.1 (68). As in humans, ADGRE1 promoters from each of
the large animals are purine-rich, but with a smaller number of
the core GGAA motifs than observed in the mouse promoter,
and with considerable variation in their location (Figure 5A).
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FIGURE 4 | Alternative splicing of ADGRE1 mRNA in mammalian macrophages. (A) Sashimi plots, created using IGV v2.4.10 (35) spanning the ADGRE1 loci of sheep
(annotation Oar v3.1; coordinates 5:15,203,349-15,289,527), goat (ARS1; 7:92,931,693-92,970,027), cattle (UMD3.1; 7:18,767,695-18,834,685), buffalo
(UMD_CASPUR_WB_2.0; NW_005785799.1:700,212-743,535), and horse (EquCab2; 7:4,424,464-4,467,628). Arrows indicate the direction of transcription. For
each species, RNA-Seq reads mapping to this locus are pooled from all available monocyte and macrophage samples. (B) Sashimi plots, created using IGV v2.4.10
(35), spanning the ADGRE1 loci of pig (annotation Sscrofa11.1; coordinates 2:72,217,039-72,306,013), human (GRCh38.p10; 19:6,887,566-6,940,459), and rat
(Rnor_6.0; 9:9,431,860-9,585,865). Arrows indicate the direction of transcription. For each species, RNA-Seq reads mapping to this locus are pooled from all
available monocyte and macrophage samples.
The FANTOM5 human CAGE datasets also reveal the presence
of an enhancer within intron 2, consistent with a previously-
published ChiP-seq analysis of human monocyte subsets (49).
This element is conserved at the sequence level in large animal
genomes (Figure 5B) and contains an identical motif to the
PU.1/IRF8 responsive element of the human IFNß1 locus (69),
which could contribute to the LPS-inducible expression of the
gene. In overview, the conservation of regulatory elements is
consistent with macrophage-specific expression in all of the
species examined.
DISCUSSION
In this study, we have combined the generation of a new
monoclonal antibody against pig ADGRE1 with detailed
informatic analysis based upon RNA-Seq to gain further insight
into the biology of ADGRE1 in mammals. The data in
Figures 1–3 show clearly thatADGRE1 is highly-expressed by pig
monocytes, tissue macrophages and granulocytes and inducible
during monocyte-macrophage differentiation from progenitors
in the bone marrow. We demonstrated the utility of this new
antibody for analysis of the response to agonists in pigs, such as
the novel pig CSF1-Fc reagent (27, 44). ADGRE1 will provide
a useful marker for dissection of infectious disease models in
pigs, especially those of the lung where the pig is clearly more
human-like (70).
The location of ADGRE1 expression in the pig revealed
two major differences from the mouse. Mouse granulocytes
express Adgre1 mRNA, but do not translate the protein (20)
whereas in pigs, ADGRE1 was highly-expressed on the surface
of granulocytes in bone marrow. Consistent with the protein
expression (45), Adgre1 mRNA is very low in mouse alveolar
macrophages (71) and we have found the same at the mRNA
level in rats (CP, DAH, manuscript in preparation). By contrast,
ADGRE1 protein was very highly-expressed in both alveolar and
interstitial macrophages in the pig, and at least at the mRNA
level, this pattern appears to be conserved in all the large animals
including humans.
We summarized evidence from multiple datasets and
platforms that the expression pattern we have dissected in
pigs is shared with humans and other large animals. ADGRE1
mRNA is not, as previously suggested, restricted in its expression
to eosinophils or even enriched in those cells in humans.
Indeed, the gene is a marker for differentiation of the CD16++
monocyte subset in human peripheral blood and is also highly-
expressed in many tissue macrophage populations, notably
those of the lung. Expression of ADGRE1 in macrophages
in all large animals is consistent with the conservation of
promoter and enhancer elements across species. Nevertheless,
where Adgre1 mRNA and protein were induced by CSF1 in
rodent macrophages, in the large animals ADGRE1 mRNA
expression in macrophages was down-regulated, compared to
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FIGURE 5 | Alignment of promoter (A) and enhancer (B) regions of mammalian ADGRE1 genes. Promoter sequences of the species shown were extracted from
Ensembl initially based upon BLAST queries with either human or mouse sequences as the query, and then aligned using CLUSTALW. The ATG start codon in each
species is in bold. The experimentally validated transcription start sites in mouse, human, pig and buffalo fall with the region immediately 5′ of the ATG (bold red).
Conserved candidate regulatory elements highlighted include Maf (red), Runx1 (purple), AP1 (green), CEBP (blue). Purine-rich binding sites for PU.1 and/or other Ets
factors are underlined. The intronic enhancer in the human gene lies at Chr19:6,892,130-8,892,530. This sequence was used to extract conserved sequences within
the ADGRE1 locus of each species from Ensembl using BLAST. No hit was obtained on rodent genomes. The conserved PU.1/IRF8 motif is highlighted in red.
monocytes and, in some species, apparently inducible by LPS
(Table S1). The pattern of regulation of ADGRE1 mRNA,
as well as its genomic location, suggests a possible role
in genetic susceptibility to inflammatory bowel disease (30).
Thus, although some promoter elements that drive macrophage
expression are conserved (Figure 5A), there is also evidence
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for evolution of transcriptional regulatory mechanisms within
selected macrophage populations.
The two previous reports of specific ADGRE1 mRNA and
protein expression in eosinophils are difficult to reconcile with
our analysis. Both reports used the same set of PCR primers,
amplifying a short product from bases 1,408 to 1,490 in the cDNA
sequence. To explain the apparent selective binding of anti-
ADGRE1 antibodies to eosinophils, there is the formal possibility
that the ADGRE1 protein is selectively translated in these
cells. Alternatively, the antibodies may cross-react with related
calcium-binding EGF domain-containing molecules such as
ADGRE3 which are actually strongly enriched in granulocytes, or
with a specific glycoform of ADGRE1 produced by eosinophils.
Whatever the explanation, it would clearly be worthwhile to
make and test additional anti-human ADGRE1 reagents.
Aside from differences in gene expression profiles, ADGRE1
also varies greatly at the protein sequence level between species,
including differences in the numbers of the EGF-like calcium
binding domains. Within a species, the EGF-like domains
also differ in sequence from each other. The mouse Adgre1
cDNA described originally encoded 7 EGF-like calcium binding
domains. Subsequent analysis of both mouse cDNAs identified at
least 5 variants differing in the inclusion of individual domains.
These included variants that lack exon 4, which contains the likely
site for glycosaminoglycan attachment (5). Human ADGRE2
shows evidence of both alternative splicing of the EGF-like
domains and regulated glycosylation (60). There is also some
evidence of alternative splicing of the humanADGRE1 transcript.
Sequencing of multiple full-length mouse macrophage cDNAs
by the FANTOM consortium (72) identified further variants,
apparently containing any combination of the EGF-like domains
and including a possible secreted isoform. The longest cloned
human ADGRE1 cDNA in Ensembl encodes 6 EGF-like calcium
binding domains, but our analysis indicates that there are actually
7 domains, as in rodents and pigs. By contrast to these species, the
longest predicted cDNA encoding ADGRE1 in other species are
considerably larger. The longest Ensembl sheep cDNA encodes
1,259 amino acids and 13 calcium binding EGF-like domains but
the RNA-Seq data suggests there is at least one additional exon.
The predicted protein for the goat is only 905 amino acids, which
is clearly incorrect since the longest Ensembl-predicted sheep
cDNA maps in its entirety to the goat genome (not shown). The
longest Ensembl-predicted cattle protein is 1,148 amino acids
and contains 12 predicted EGF-like calcium binding domains.
However, the RNA-Seq data indicates the existence of at least
two additional exons and the entire sheep cDNA maps to the
cattle genome. Longer forms of ADGRE1 are also predicted by
Ensembl for cat (1,101 amino acids) and dog (1,162 amino acids),
but here again, the entire sheep cDNA maps contiguously to
the dog and cat genome (not shown). In overview, the longer
forms in ruminants, horses, cats, and dogs probably encode 14
EGF-like domains arising from a duplication of the 7-domain
structure of rodent, pig and human. Five of the additional
domains contain the acidic motif (most commonly CEDxDEC)
implicated in calcium binding which is present in 5 of the 7
EGF-like domains of mouse Adgre1 (5). Splicing analysis of the
RNA-Seq data derived from BMDM (Figures 4A,B) from each
of these species reveals that as in mouse, human and pig, each
of the EGF-like domains, encoded by single exons, in frame,
exhibit evidence of exon-skipping, with the potential to produce
numerous different isoforms. The protein sequence of ADGRE1
is highly divergent amongst species. For example, mice and pigs
have only 58% identity, and a dN/dS ratio of only 0.24 (obtained
via Ensembl using methods detailed at https://www.ensembl.
org/info/genome/compara/homology_method.html). Almost all
coding differences reside in the extracellular domain. In the
EGF-like domains, only the structural and calcium-binding
motifs are conserved. This may imply that there is no
evolutionary/functional constraint on the sequence of these
domains other than preservation of structure. The human exome
database (http://exac.broadinstitute.org) reveals that ADGRE1
(EMR1) is also polymorphic in human populations, with
numerous non-synonymous protein-coding variants with high
allele frequencies. Interestingly, a missense splice donor site,
with a population allele frequency of 0.38, might explain the
apparent lack of one exon in the longest current human
cDNA. Alternatively, the rapid evolution of protein-coding
sequences, and gene duplication, has long been recognized as
a feature of immune-associated genes (73). Both within species
polymorphism and accelerated between species divergence of
innate immune genes was highlighted in detailed analysis of the
pig immunome (74).
Hamann et al. (7) reviewed the evidence that members of the
adhesion G protein coupled receptor family [ADGRE1, ADGRE2,
ADGRE3, ADGRE4, and CD97 (akaADGRE5)] aremodulators of
immune cell function. Analysis of the function of this gene family
has been constrained by the lack of knowledge of likely ligands.
The only evidence comes from ADGRE2 which was reported
to bind selectively to the proteoglycan chondroitin sulfate (75).
Interaction with various glycosaminoglycans (GAG) at portals
of entry is a very common feature of microbial pathogenesis
(76). Conceivably, host GAG might act as opsonins to bind
pathogens to innate immune cells through the ADGRE family.
In the case of ADGRE1, no ligand has been identified, but the pig
ADGRE1 fusion protein we used as an immunogen in the current
study will facilitate future binding studies. The diversification
of the extracellular domain through evolutionary selection and
splicing, and high expression in lung macrophages in pigs,
humans and other large animals, support the hypothesis that
ADGRE1 has evolved in response to selection by pathogens, and
participates in the host defense. A recent report demonstrated
that cross-linking with anti-ADGRE2 antibody produced a pro-
inflammatory signal in a human monocytic cell line (77). To
our knowledge, the widely-used anti-mouse ADGRE1 antibody,
F4/80, has not been shown to generate a detectable signal
when added to macrophages. The availability of anti-ADGRE1
antibodies for the pig will enable further functional studies in this
species that may translate to humans and other species.
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